Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino Sells 4,000 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $5.38, for a total transaction of $21,520.00. Following the transaction, the director now directly owns 64,334 shares in the company, valued at $346,116.92. This represents a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mark Alvino also recently made the following trade(s):

• On Tuesday, January 21st, Mark Alvino sold 4,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.10, for a total value of $20,400.00.

Abeona Therapeutics Stock Up 1.3 %

NASDAQ:ABEO traded up $0.07 during trading hours on Friday, reaching $5.54. The company’s stock had a trading volume of 237,491 shares, compared to its average volume of 302,800. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a 50 day moving average price of $5.74 and a two-hundred day moving average price of $5.72. Abeona Therapeutics Inc has a 12 month low of $3.05 and a 12 month high of $9.01. The company has a market capitalization of $240.82 million, a P/E ratio of -2.06 and a beta of 1.46.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 9th.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after purchasing an additional 429,456 shares during the period. abrdn plc lifted its position in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after acquiring an additional 200,647 shares during the last quarter. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its holdings in Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.